高级检索
当前位置: 首页 > 详情页

UHRF1 is an Independent Prognostic Factor and a Potential Therapeutic Target of Esophageal Squamous Cell Carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Jinan Univ, Dept Pathol, Med Coll, Guangzhou 510632, Guangdong, Peoples R China [2]Jinan Univ, Guangdong Prov Key Lab Mol Immunol & Antibody Eng, Guangzhou 510632, Guangdong, Peoples R China [3]Huazhong Univ Sci & Technol,Inst Pathol,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Hubei,Peoples R China
出处:
ISSN:

关键词: DNA methylation esophageal squamous cell carcinoma prognosis UHRF1 Wee1

摘要:
Purpose: Ubiquitin-like with plant homeodomain and ring-finger domains 1 (UHRF1) plays an essential role in DNA methylation, and the overexpression of UHRF1 is associated with poor prognosis in various cancers. Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of esophageal cancer cases in China, but the five-year survival rate for patients is less than 10% due to limited clinical approaches for early diagnosis and treatment. The present research aimed to investigate the expression of UHRF1 in ESCC and its biological role in ESCC development. Methods: UHRF1 expression in ESCC and normal esophageal tissues was examined using immunohistochemical staining, followed by analysis of the correlation between UHRF1 expression and clinical features. In addition, the effects of lentivirus-mediated RNA interference of UHRF1 on global DNA methylation, cell proliferation, cell cycle progression and apoptosis and were investigated in ESCC cells. Results: UHRF1 was overexpressed in ESCC tissues and was an independent prognostic factor for ESCC patients. In ESCC cells, knockdown of UHRF1 caused global DNA hypomethylation, inhibited cell proliferation and induced apoptosis. Furthermore, UHRF1 depletion induced cell cycle arrest at the G2/M phase, accompanied by activation of Wee1 and DNA damage response pathway. Conclusions: Our findings identify UHRF1 as a promising prognostic marker for ESCC and suggest that UHRF1 may be a potential therapy target for ESCC patients with elevated UHRF1 expression.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q2 ONCOLOGY
最新[2024]版:
Q2 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者单位: [1]Jinan Univ, Dept Pathol, Med Coll, Guangzhou 510632, Guangdong, Peoples R China [2]Jinan Univ, Guangdong Prov Key Lab Mol Immunol & Antibody Eng, Guangzhou 510632, Guangdong, Peoples R China
通讯作者:
通讯机构: [1]Jinan Univ, Dept Pathol, Med Coll, Guangzhou 510632, Guangdong, Peoples R China [2]Jinan Univ, Guangdong Prov Key Lab Mol Immunol & Antibody Eng, Guangzhou 510632, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:622 今日访问量:1 总访问量:452 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)